Fares Qeadan

researcherMale0.0Global Dominance: 0.00%

Fares Qeadan is a researcher at Loyola University Chicago who has contributed to the discussions around the potential use of GLP-1 medications in treating substance addiction. His insights emphasize the significance of these findings for health professionals, suggesting that the results could influence prescribing practices for metabolic conditions.

Power0

Reach0

Collect

Not in the pool (under ¢1).

Recent news mentions

Fares Qeadan from the Parkinson School of Health Sciences and Public Health in Chicago comments on the need for more evidence before prescribing Ozempic to all addiction patients.

Ozempic reduziert Drogenkonsum: neue Hoffnung für Süchtige

Neue Zürcher Zeitung·

Switzerland· 2026-03-07

6.0

Also mentioned

Jaap Arriens

Carolina Haass Koffler

Ziyad Al Ali

Joseph Schacht

Fares Qeadan notes that traditional treatments remain a priority, but these results should be considered by doctors when prescribing GLP-1 for metabolic reasons.

fármacos para la obesidad y la diabetes podrían ayudar a combatir adicciones, revelan investigaciones

Prensa Libre – major Guatemalan newspaper, est. 1951·

Guatemala· 2026-03-07

7.0

Also mentioned

Ziyad Al Aly